DK3045471T3 - Rekombinant FSH med alfa-2,3- og alfa-2,6-sialylering - Google Patents

Rekombinant FSH med alfa-2,3- og alfa-2,6-sialylering Download PDF

Info

Publication number
DK3045471T3
DK3045471T3 DK16158141.8T DK16158141T DK3045471T3 DK 3045471 T3 DK3045471 T3 DK 3045471T3 DK 16158141 T DK16158141 T DK 16158141T DK 3045471 T3 DK3045471 T3 DK 3045471T3
Authority
DK
Denmark
Prior art keywords
fsh
leu
lys
rfsh
sialylation
Prior art date
Application number
DK16158141.8T
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3045471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK3045471T3 publication Critical patent/DK3045471T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (3)

1. Fremgangsmåde til fremstilling af rFSH med a-2,3- og a-2,6,-sialylering, hvilken fremgangsmåde omfatter et trin, hvor der dannes eller udtrykkes rFSFl i en Per.C6-cellelinje( hvor Per.C6-cellelinjen er blevet manipuleret til at udtrykke en a-2,3-sialyltransferase.
2. Fremgangsmåde ifølge krav 1, hvor Per.C6-cellelinjen har endogen a-2,6-sialyl-transferaseaktivitet.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor 10 % til 90 % af den samlede sialylering er a-2,3-sialylering.
DK16158141.8T 2008-04-16 2009-04-16 Rekombinant FSH med alfa-2,3- og alfa-2,6-sialylering DK3045471T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
DK3045471T3 true DK3045471T3 (da) 2017-06-26

Family

ID=39717519

Family Applications (4)

Application Number Title Priority Date Filing Date
DK16158141.8T DK3045471T3 (da) 2008-04-16 2009-04-16 Rekombinant FSH med alfa-2,3- og alfa-2,6-sialylering
DK16194925.0T DK3144318T3 (da) 2008-04-16 2009-04-16 Rekombinant fsh, der omfatter alpha 2,3- og alpha 2,6-sialylering
DK09733497.3T DK2268666T3 (da) 2008-04-16 2009-04-16 Rekombinant FSH indbefattende alpha-2,3- og alpha-2,6-sialylering
DK14178729.1T DK2808340T3 (da) 2008-04-16 2009-04-16 Rekombinant fsh inkluderende alpha-2,3- og alpha-2,6-sialylering.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK16194925.0T DK3144318T3 (da) 2008-04-16 2009-04-16 Rekombinant fsh, der omfatter alpha 2,3- og alpha 2,6-sialylering
DK09733497.3T DK2268666T3 (da) 2008-04-16 2009-04-16 Rekombinant FSH indbefattende alpha-2,3- og alpha-2,6-sialylering
DK14178729.1T DK2808340T3 (da) 2008-04-16 2009-04-16 Rekombinant fsh inkluderende alpha-2,3- og alpha-2,6-sialylering.

Country Status (29)

Country Link
US (6) US8951967B2 (da)
EP (7) EP2808340B1 (da)
JP (7) JP2011519359A (da)
KR (5) KR20180095140A (da)
CN (3) CN105906703A (da)
AR (1) AR071479A1 (da)
AU (5) AU2009237479B2 (da)
BR (1) BRPI0910461B8 (da)
CA (1) CA2725257A1 (da)
CY (1) CY1115413T1 (da)
DK (4) DK3045471T3 (da)
ES (3) ES2468318T3 (da)
FR (1) FR17C1020I2 (da)
HK (2) HK1146284A1 (da)
HR (3) HRP20140535T1 (da)
HU (5) HUE033830T2 (da)
IL (2) IL208538A (da)
LT (5) LT3098234T (da)
MX (3) MX2010011343A (da)
NO (2) NO2017025I1 (da)
NZ (1) NZ588381A (da)
PL (4) PL3144318T3 (da)
PT (4) PT2808340T (da)
RU (3) RU2682270C2 (da)
SA (1) SA109300228B1 (da)
SI (4) SI3144318T1 (da)
TW (1) TWI488640B (da)
WO (1) WO2009127826A1 (da)
ZA (1) ZA201007373B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
SI2621517T2 (sl) 2010-09-29 2023-11-30 Ferring B.V. Sestavek za uporabo pri zdravljenju neplodnosti
US20130224797A1 (en) 2010-10-15 2013-08-29 Jcr Pharmaceuticals Co., Ltd. Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9657310B2 (en) * 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
DK3283097T3 (da) 2015-04-17 2020-04-20 Ferring Bv Fsh til behandling af infertilitet
WO2016207353A1 (en) 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
JOP20200034A1 (ar) 2017-09-01 2020-02-13 Ferring Bv تركيبة للتنشيط المتحكم فيه للمبيض
JP2021522268A (ja) 2018-04-30 2021-08-30 フェリング ベスローテン フェンノートシャップ 制御された卵巣刺激のための組成物
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
AU2022451605A1 (en) 2022-04-01 2024-09-26 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
CN1608078B (zh) * 2001-10-22 2012-07-25 默克雪兰诺有限公司 用于卵泡生成的促性腺激素
DK1440157T3 (da) 2001-10-29 2012-05-07 Crucell Holland Bv Methods and means for producing proteins with predetermined post-translational modifications
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
CA2554968C (en) 2004-02-04 2012-03-27 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
US8609370B2 (en) * 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
EP2600809B1 (en) 2010-08-03 2015-02-25 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
SI2621517T2 (sl) 2010-09-29 2023-11-30 Ferring B.V. Sestavek za uporabo pri zdravljenju neplodnosti
EP2691119B1 (en) 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
EP3045471A1 (en) 2016-07-20
HK1146284A1 (en) 2011-05-20
PL2808340T3 (pl) 2017-02-28
US11952407B2 (en) 2024-04-09
LT3098234T (lt) 2024-09-10
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
DK2808340T3 (da) 2016-12-05
JP2024038000A (ja) 2024-03-19
EP3098234B1 (en) 2024-07-31
AU2014203277B2 (en) 2017-04-06
BRPI0910461A8 (pt) 2018-10-16
SI3045471T1 (sl) 2017-07-31
HUS1700025I1 (hu) 2017-06-28
RU2010141908A (ru) 2012-05-27
US20180079794A1 (en) 2018-03-22
ZA201007373B (en) 2011-06-29
HRP20170958T1 (hr) 2017-09-22
ES2468318T3 (es) 2014-06-16
SI3144318T1 (sl) 2020-12-31
EP3045471B1 (en) 2017-03-29
EP2268666B1 (en) 2014-03-12
HUS1700036I1 (hu) 2017-10-30
CA2725257A1 (en) 2009-10-22
JP7316905B2 (ja) 2023-07-28
BRPI0910461A2 (pt) 2018-03-27
AU2014203277A1 (en) 2014-07-24
US20240327487A1 (en) 2024-10-03
NO2017050I1 (no) 2017-09-28
AU2017204259A1 (en) 2017-07-20
JP2011519359A (ja) 2011-07-07
RU2014141994A3 (da) 2018-05-28
JP6762916B2 (ja) 2020-09-30
AU2014203277C1 (en) 2017-07-27
SI2808340T1 (sl) 2016-12-30
AR071479A1 (es) 2010-06-23
JP2022031652A (ja) 2022-02-22
US20160347811A1 (en) 2016-12-01
KR20190092608A (ko) 2019-08-07
BRPI0910461B8 (pt) 2021-05-25
AU2017225020B2 (en) 2019-11-14
PT3045471T (pt) 2017-06-14
KR20170110741A (ko) 2017-10-11
PL3144318T3 (pl) 2021-02-08
US10995128B2 (en) 2021-05-04
EP2808340A1 (en) 2014-12-03
KR20160056960A (ko) 2016-05-20
KR20110005863A (ko) 2011-01-19
US9771407B2 (en) 2017-09-26
HRP20161520T1 (hr) 2016-12-30
EP3144318A1 (en) 2017-03-22
KR101622944B1 (ko) 2016-05-23
RU2745557C1 (ru) 2021-03-29
AU2009237479B2 (en) 2014-05-15
JP2020040956A (ja) 2020-03-19
DK2268666T3 (da) 2014-05-12
FR17C1020I1 (da) 2020-04-10
HUE033830T2 (en) 2018-01-29
HK1199039A1 (en) 2015-06-19
CN102066414A (zh) 2011-05-18
EP4015527A1 (en) 2022-06-22
LT3045471T (lt) 2017-07-10
PL2268666T3 (pl) 2014-08-29
SA109300228B1 (ar) 2014-04-08
PT3144318T (pt) 2020-11-04
US20210332099A1 (en) 2021-10-28
ES2629392T3 (es) 2017-08-09
WO2009127826A1 (en) 2009-10-22
DK3144318T3 (da) 2020-12-07
EP3098234A1 (en) 2016-11-30
LTPA2017018I1 (lt) 2017-06-26
JP6486310B2 (ja) 2019-03-20
RU2682270C2 (ru) 2019-03-18
CY1115413T1 (el) 2017-01-04
HUE030652T4 (en) 2017-09-28
JP2015120696A (ja) 2015-07-02
RU2014141994A (ru) 2016-05-10
MX348622B (es) 2017-06-22
US20150065695A1 (en) 2015-03-05
IL208538A (en) 2014-03-31
US9546204B2 (en) 2017-01-17
PT2808340T (pt) 2016-11-21
US20110105398A1 (en) 2011-05-05
KR102108377B1 (ko) 2020-05-08
IL230571A (en) 2015-11-30
HUS1700024I1 (hu) 2017-06-28
SI2268666T1 (sl) 2014-07-31
PT2268666E (pt) 2014-06-25
RU2745557C3 (ru) 2021-12-10
AU2017204258A1 (en) 2017-07-20
CN105906703A (zh) 2016-08-31
AU2009237479A1 (en) 2009-10-22
AU2017204259B2 (en) 2017-08-17
AU2017225020A1 (en) 2017-09-28
JP2018021037A (ja) 2018-02-08
BRPI0910461B1 (pt) 2021-02-23
PL3045471T3 (pl) 2017-10-31
TWI488640B (zh) 2015-06-21
CN105906702A (zh) 2016-08-31
EP2808340B1 (en) 2016-08-17
JP2017060476A (ja) 2017-03-30
LT2808340T (lt) 2016-11-10
FR17C1020I2 (fr) 2020-04-10
IL208538A0 (en) 2010-12-30
EP2722339A1 (en) 2014-04-23
HUE030652T2 (en) 2017-05-29
US8951967B2 (en) 2015-02-10
RU2537268C2 (ru) 2014-12-27
EP2268666A1 (en) 2011-01-05
NO2017025I1 (no) 2017-06-06
NZ588381A (en) 2012-05-25
LTPA2017029I1 (lt) 2017-10-10
EP3144318B1 (en) 2020-09-23
MX355457B (es) 2018-04-19
AU2017204258B2 (en) 2017-08-17
TW200948378A (en) 2009-12-01
MX2010011343A (es) 2011-01-20
KR20180095140A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
US11952407B2 (en) Pharmaceutical preparation